Prognostic studies suggest that FTO can predict poor outcomes in glioma patients, and inhibitors targeting FTO have shown promise in reducing tumorigenicity and aggressiveness in glioma models [139,140,141,142]. The gene discussed is FTO; the disease is central nervous system cancer.